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Background. End-stage renal disease (ESRD) is epidemic
worldwide. In Hong Kong, the annual incidence of ESRD has
risen from 100 pmp (per million population) in 1996 to 140 pmp
in 2003. SHARE (Screening for Hong Kong Asymptomatic Re-
nal Population and Evaluation program) is a population-based
screening program aimed at identifying the prevalence of un-
recognized renal disease in asymptomatic individuals, allowing
further evaluation and disease-modifying interventions.
Methods. From November to December 2003, SHARE was
conducted in several large residential communities in Hong
Kong. The screening tool included a questionnaire documenting
demographics and history or family history of diabetes mellitus
(DM), hypertension (HT), and chronic kidney disease (CKD),
together with on-site measurements of blood pressure (BP) and
urine dipstick for protein, blood, and glucose.
Results. There were a total of 1811 participants. One thou-
sand two hundred and one subjects were entered into the fi-
nal analysis. Among the 1201 who were apparently “healthy”
(asymptomatic and without history of DM, HT, or CKD), the
prevalence of positive (≥1+) urine dipstick for protein, glu-
cose, blood, protein or blood, any urine abnormality, and HT
(BP≥140/90) was 3.2%, 1.7%, 13.8%, 16%, 17.4%, and 8.7%,
respectively. Thirty three percent of the age over 60 years old
group had either hypertension or urine abnormalities, com-
pared with 24.0% in the 41- to 60-year-old group and 9.7% in
the 20- to 40-year-old group. Having a family history of diabetes
or hypertension increases the risk of having urine abnormali-
ties, while a family history of hypertension also increases the
risk of high blood pressure.
Conclusion. It is concluded that subclinical abnormalities in
urinalysis or BP readings are prevalent across all age groups
in the adult population. An effective screening program at the
primary care level that identifies these subjects for further eval-
uation is warranted, and the public in Hong Kong should be
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educated toward the significance of such findings in order to
have regular health check for asymptomatic renal diseases.
End-stage renal disease (ESRD) is epidemic world-
wide, and it imposes substantial patient morbidity and
mortality. It greatly affects the quality of life of an indi-
vidual, and consumes a large portion of the health care
expenditure of a society [1].
In Hong Kong, the annual incidence of new cases of
ESRD requiring renal replacement therapy (RRT) has
risen from 100 per million population (pmp) in 1996 to
139 pmp in 2003 [2]. Currently, there are 6000 patients in
Hong Kong requiring RRT [2]. In year 2004, 38% of the
cases of ESRD were due to diabetes mellitus, 23% were
caused by nephritis, 10% by hypertension. About 16%
were due to unknown etiologies, usually presenting with
late stage renal failure [2].
Early chronic kidney disease (CKD) has few symptoms
and is frequently unrecognized. There are practice guide-
lines published recently recommending routine testing
for undetected kidney disease during health care encoun-
ters for individuals who are at risk for chronic kidney
disease (CKD) [3].
SHARE (Screening for Hong Kong Asymptomatic
Renal population and Evaluation program) is a
population-based screening program aimed at identify-
ing the prevalence of ‘silent’ renal disease in Hong Kong.
Such population-based screening programs are intended
to estimate the prevalence of early renal disease. Further
evaluation and disease-modifying interventions (educa-
tional programs, monitoring, pharmacologic means) may
then be instituted to delay, or even prevent, subsequent
progression to end-stage renal disease [4]. It is hoped
that SHARE will also help to determine the prevalence
of known risk factors (e.g., DM, hypertension), and to
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Table 1. Prevalence of abnormal urine results among asymptomatic subjects
Age range 20 to 40 41 to 60 >60 Total
N 226 641 334 1201
Urine abnormality
Urine protein (≥1+) 6 (2.7%) 20 (3.1%) 13 (3.9%) 39 (3.2%)
Urine sugar (≥1+) 3 (1.3%) 11 (1.7%) 7 (2.1%) 21 (1.7%)
Urine RBC (≥1+) 13 (5.8%) 91 (14.2%) 62 (18.6%) 166 (13.8%)
Any urine abnormalitya 20 (8.8%) 113 (17.6%) 76 (22.8%) 209 (17.4%)
aRefers to dipstick-positive protein, blood, and/or sugar occurring either singly or in combination.
generate data to guide the planning of secondary and ter-
tiary renal services.
METHODS
From November to December 2003, SHARE was
conducted in several large residential communities in
Hong Kong, including both public and private housing
estates.
The first part of the screening tool is a questionnaire
documenting demographics (sex, ethnicity, and age) and
occupation. Subjects were asked about personal medical
history of diabetes mellitus (DM), hypertension (HT),
and chronic kidney disease (CKD), and where they were
receiving treatment (private or public sector). Personal
history of DM, HT, or CKD was defined as a positive
answer to the question “Have you ever been told by a
doctor that you have DM, HT, or CKD?” Family history
regarding DM, HT, and CKD was likewise defined as a
positive response to the question “Do(es) your family
member(s) have DM, HT, or CKD?”
The second part of the screening included the following
on-site measurements: (1) body weight and height; (2) a
clean-catch, midstream, random urine specimen for dip-
stick urinalysis (Labstix, Bayer HealthCare Diagnostics,
Brigend, South Wales, UK) for protein, blood, and sugar;
and (3) blood pressure measurement. Blood pressure was
taken in a seated position using an automated sphygmo-
manometer as an average of two readings after the subject
rested for at least five minutes. If either reading showed a
systolic ≥140 mm Hg or diastolic blood pressure ≥90 mm
Hg, then a third reading would be taken into account in
calculating the mean blood pressure readings.
Statistical analysis
Data entry and management were performed on
Microsoft Excel. All analyses and calculations were per-
formed by using SPSS statistical package, version 10.0
(SPSS, Inc., Chicago, IL, USA). Estimates of point preva-
lence were presented with 95% confidence intervals.
Where prevalence data were expressed as number of per-
sons needed to be screened to identify one subject with an
abnormality of interest, the value was calculated by the
reciprocal of the prevalence of the abnormality, together
Table 2. Prevalence of abnormal blood pressure among
asymptomatic subjects
Age range 20 to 40 41 to 60 >60 Total
N 226 641 334 1201
BP abnormality
HNBP (130–139/ 2 (0.9%) 25 (3.9%) 2 (0.6%) 29 (2.4%)
85–89)
HT (≥140/90) 2 (0.9%) 57 (8.9%) 45 (13.5%) 104 (8.7%)
ISH (≥140/<90) 11 (4.9%) 67 (10.5%) 121 (36.2%) 199 (16.6%)
Abbreviations are: ISH, isolated systolic hypertension; HNBP, high-normal
blood pressure.
with 95% confidence interval estimates. P values of less
than 0.05 were considered significant.
RESULTS
A total of 1811 subjects participated in the screening
program. One hundred and eight people were not eligible
for analysis. Reasons for exclusion included age less than
20 years old, current menstruation, or incomplete data.
Another 502 were known to have a personal history of
diabetes, hypertension, or chronic kidney disease.
One thousand two hundred and one asymptomatic sub-
jects were entered into the final analysis. There were 417
males (34.7%). Mean age was 53 years old, median age
was 52 years old (range 20 to 89 years old). Fifty-three
percent were between 41 to 60 years old.
Among them, 209 (17.4%) people were found to have
abnormalities in urine multistix. The proportion of peo-
ple screened having urine abnormalities increases with
age. Among the elderly group (>60 years old), 22.8% had
urine abnormalities, followed by 17.6% and 8.8% in the
age 41 to 60 and 20 to 40 groups, respectively. Overall, 166
(13.8%) subjects had microscopic hematuria (urine red
blood cell ≥1+), 39 (3.2%) had proteinuria (urine albu-
min ≥1+), and 21 (1.7%) had glycosuria (urine glucose
≥1+). There were 192 (16.0%) people with either pro-
teinuria or hematuria, while 13 (1.1%) had both hema-
turia and proteinuria (Table 1).
A total of 104 people (8.7%) had hypertension (BP
≥140/90 mm Hg), 199 (16.6%) had isolated systolic hy-
pertension (BP ≥140/<90 mm Hg), while another 29
(2.4%) had high-normal blood pressure (BP 130–139/85–
89) (Table 2).
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Table 3. Prevalence of combined blood pressure and urine abnormalities
Age range 20 to 40 41 to 60 >60 Total
N 226 641 334 1201
Any blood pressure or urine abnormality
HT or any urine abnormality 22 (9.7%) 154 (24%) 111 (33.2%) 287 (23.9%)
Blood pressure and urine abnormality
HT and urine protein (≥1+) 0 7 (1.1%) 5 (1.5%) 12 (1%)
HT and urine RBC (≥1+) 0 13 (2%) 8 (2.4%) 21 (1.7%)
HT and urine protein or RBC (≥1+) 0 16 (2.5%) 10 (3%) 26 (2.2%)
HT, hypertension is defined as BP ≥140/90 mm Hg.
Table 4. NNS (Number needed to screen) to detect one
asymptomatic person with an abnormality and positive family history
Among subjects
with positive Among all
family history subjects
Any urine abnormality with FDM
All 5 6
>60 years 5 4
41 to 60 years 5 6
20 to 40 years 7 11
Any urine abnormality with FHT
All 5 6
>60 years 4 4
41 to 60 years 5 6
20 to 40 years 8 11
Abnormal blood pressure with FHT
All 8 12
>60 years 6 7
41 to 60 years 7 11
20 to 40 years 28 113
FDM/FHT, family history of diabetes or hypertension.
When the on-site measurements were combined, 287
people (23.9%) were found to have either blood pressure
or urine abnormalities. Thirty-three percent of the >60-
year-old group had either hypertension or urine abnor-
malities compared with 24.0% in the 41- to 60-year-old
group and 9.7% in the 20- to 40-year-old group (Table 3).
Family history was confirmed to be a risk factor for
urine abnormalities or hypertension. To identify one
person with urine abnormality among subjects of age 20
to 40 in this “healthy” cohort, the number of persons
needed to screen (NNS) was 11. Among those with fam-
ily history of DM or HT, the NNS was 7 or 8, respectively.
Similarly, to identify one person with abnormal blood
pressure among the subjects of age 20 to 40, the NNS was
113, while with positive family history of HT, the NNS
drops to 28 (Table 4).
Overall, the NNS to detect an asymptomatic subject
with any urine abnormality was 6, while that for hyper-
tension is 12. The NNS to detect one asymptomatic per-
son with any urine or blood pressure abnormality is 4
(Table 5).
DISCUSSION
In SHARE, the prevalence of proteinuria among
asymptomatic subjects was 3.2%. It was slightly higher
Table 5. Numbers-needed-to-screen (NNS) to detect one




>60 years 4 4–5
41 to 60 years 6 5–7
20 to 40 years 11 8–19
Hypertension
All 12 10–14
>60 years 7 6–10
41 to 60 years 11 9–15
20 to 40 years 113 47–a
ISH in subjects >60 years old 3 2–3
Any urine abnormality or hypertension
All 4 4–5
>60 years 3 3–4
41 to 60 years 4 4–5
20 to 40 years 10 7–17
Urine abnormality, urine dipstick for protein, blood, or glucose of ≥1+.
Hypertension = BP ≥140/90 mm Hg. ISH, isolated systolic hypertension (BP
≥140/<90 mm Hg).
aAn estimate was not interpretable due to limited number of participants.
than the 2.4% found in AusDiab [6], which took place
from 1999 to 2000 and screened over 11,000 adults. It
was significantly higher than that found in NHANES III
(0.3%) [7] and NKFS Prevention Program (1.1%) [8]
(Table 6). One possible explanation for these similarities
and differences is that the mean age in our cohort was
comparable to that in AusDiab (53 vs. 51.5 years), but
significantly higher than in the other two programs. The
much younger age (36.3 years) in the NKFS Prevention
Program is likely related to their selection of the working
population as their primary screening target.
An effective screening program makes use of accept-
able tests that can accurately and reliably detect relatively
asymptomatic disease at an early stage. Ideally, this will
allow an effective treatment, resulting in improved out-
comes when compared with an unscreened population.
Its value increases if there is a significant prevalence of the
disease in the population, and a considerable proportion
of the target population has preclinical or asymptomatic
disease [9, 10]. It is more cost effective if the ‘number
needed to screen’ (NNS) is small. SHARE was proved to
be an effective screening program for ‘silent’ renal dis-
ease, and was more effective for the older population.
The NNS for any blood pressure or urine abnormality in
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Table 6. Table comparing the results of various screening programs worldwide
NHANES NKFS Prevention SHARE
Program title III [7] Program [8] AusDiab [6] (Present study)
Country of origin USA Singapore Australia Hong Kong
Year of screening 1988 to1994 1997 to 2001 1999 to 2000 2003
Age range ≥20 years Working adults ≥25 years ≥20 years
N (total) 14,622 189,117 11,247 1703
N (asymptomatic) 8585 169,552 (estimated Not mentioned 1201
minimum no.)
Mean age years 20 to 39 (46%) 36.3 51.5 56.4 (N = 1703)
53 (N = 1201)
Race White (80%) Chinese (77%) Australian of European Chinese (>99%)
descent (90%); Asian (7%)
Black (11%) Malay (11%)
Mexican (5%) Indian (9%)
Prevalence of proteinuria 1% (N = 14,622) 1.10% 2.40% 5.0% (N = 1703)
0.3% (N = 8585) 3.2% (N = 1203)
asymptomatic subjects was 4 in the whole group: 3 for the
>60 years old, 4 for the 41- to 60-year-olds, and 10 for the
20- to 40-year-olds, respectively.
There are recent practice guidelines recommending the
implementation of at-risk screening for CKD. Support
for a population-based CKD screening strategy should
be based on the characteristics of CKD in the population
and the health system of the involved population [11].
CKD is known to cause substantial impairment on the
quality of life of affected individuals and their families
[12, 13]. It has a prolonged latent period during which
the disease is asymptomatic. Symptoms associated with
uremia do not usually appear until glomerular filtration
rate (GFR) is less than 30 mL/min. Thus, there is a sub-
stantial range of GFR during which patients with CKD,
with a GFR of 60 mL/min or less, may be asymptomatic,
and where screening is justified. The early detection of
CKD can allow implementation of treatment to delay
or prevent the occurrence of significant morbidity and
mortality. Management includes aggressive control of di-
abetes mellitus and hypertension in affected individuals.
The NKF-KDOQI guidelines recommend that individu-
als be screened for CKD using a spot urine for protein
and an estimate of GFR based on serum creatinine [3].
However, these recommended screening tests might be
less suitable for large-scale population-based screening.
The ability of using a standard dipstick to detect CKD
has not been systematically analyzed for its sensitivity
and specificity for predicting eventual ESRD. However,
in a study evaluating the relationship between a single
random dipstick proteinuria and albumin-to-creatinine
ratio, there was a 91% positive predictive value of pos-
itive (≥1+) dipstick proteinuria for clinically significant
quantitated proteinuria in both diabetic and nondiabetic
populations [14]. Also, a single episode of dipstick posi-
tive proteinuria was found to be a significant predictor
for all-cause, as well as cardiovascular, mortality [15].
Thus, these studies support the value of screening by dip-
stick proteinuria in the early detection of CKD and its
complications.
SHARE showed that occult urine or blood pressure
abnormalities are prevalent in Hong Kong. It also con-
firmed that family history of diabetes or hypertension
is a strong predictor of renal disease. This was similar
to findings from previous study among family members
of ESRD patients [5]. Although silent renal diseases are
more prevalent as age increases, they may also occur in
young asymptomatic subjects.
CONCLUSION
Apart from screening, facilities for follow-up evalua-
tion should be made available to all screened-positive
subjects. Long-term follow-up and disease-modifying
treatment should be available to those confirmed to
have CKD. There are now detection and prevention pro-
grams for hypertension and diabetes set up in Singapore
and parts of India [16]. Both have shown results in the
short term in controlling hypertension and diabetes, and
hopefully, will, in the long run, delay or prevent the pro-
gression of CKD. Apart from nephrologists and diabetol-
ogists, primary care physicians should also be educated
in the management of individuals with CKD. The public
should also bear the responsibility in taking care of their
own health by regular health checks, especially those with
family history of renal disease, hypertension, or diabetes.
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